Tat analog (CPP) + AT1002 analog (TJ modulator)
Sequence: GRKKRRQRRRCG
| Experiment Id | EXP001397 |
|---|---|
| Paper | Therapeutic Effects on Atopic Dermatitis by Anti-RelA Short Interfering RNA Combined with Functional |
| Peptide | Tat analog (CPP) + AT1002 analog (TJ modulator) |
| Delivery Success Class | no |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | Tat 32 µg + AT1002 400 µg co-applied with siRNA (single topical dose) |
| Rna Concentration | FAM-siRNA 5 µg in 25 µL (topical on tape-stripped back skin) |
| Mixing Ratio | Tat/siRNA complex + AT1002 (co-applied); N/P not specified for this imaging experiment |
| Formulation Format | Tat/siRNA complex co-administered with AT1002 (topical) |
| Formulation Components | Tat analog + AT1002 analog + FAM-siRNA |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | ICR mouse (tape-stripped back skin permeability model) |
| Administration Route | Topical (skin application) |
| Output Type | Skin penetration / distribution by confocal microscopy; ZO-1 immunostaining (tight junction disruption) |
| Output Value | |
| Output Units | |
| Output Notes | FAM-siRNA signal detected in deep epidermis with Tat+AT1002; ZO-1 signal reduced/absent 10–24 h after application (tight junction opening). |
| Toxicity Notes | AT1002 described as a non-toxic tight-junction modulator peptide; no acute toxicity reported for topical dosing. |
| Curation Notes |